Beyond Generics: Venkat Nelabhotla Unveils the ‘Develop, Own, Make’ Blueprint for India’s Global Biotech Ascension

At the 17th Annual Pharma Leaders Summit, the Vyome CEO lays out a hyper-efficient cross-border model to transform India from a high-volume manufacturer into a high-value intellectual property powerhouse.

At the prestigious 17th Annual Healthcare Leadership Summit & Power Brand Awards—widely recognized as the “Oscars of Indian Healthcare”—Mr. Venkat Nelabhotla, Co-Founder, President, CEO, and Board Member of Vyome Holdings, Inc. and Vyome Therapeutics, Inc., delivered a paradigm-shifting address.

Speaking before an audience of global healthcare executives, clinical innovators, and policymakers, Nelabhotla challenged the conventional narrative of India as merely the “pharmacy of the world” via low-cost generic volumes. Instead, he presented a bold blueprint titled “India’s Next Biotech and Pharma Innovation Leap: Develop, Own, Make, and Commercialize for the World.”

Moving From Volume to Value: The Core Pillars

Nelabhotla’s presentation laid out four foundational drivers engineered to elevate India from a cost-efficient manufacturer into an undisputed global life sciences innovation hub.

1. DEVELOP: Intellectual Property & Deep Science

The first step requires a shift from reverse-engineering to pioneering first-in-class or best-in-class therapeutics. Nelabhotla highlighted Vyome’s own breakthrough clinical pipeline—specifically VT-1953, a targeted development asset targeting malignant fungating wounds—as an example of solving severe, underserved global medical conditions.

2. OWN: The “US-India Innovation Corridor”

Nelabhotla argued passionately that true enterprise value resides in owning the molecule. He shared how Vyome pioneered a hyper-capital-efficient R&D model: inventing and securing intellectual property using India’s world-class scientific talent pool, then validating those assets through rigorous US FDA regulatory pathways.

3. MAKE: Advanced Manufacturing & Bioprocessing

While India already boasts a massive, FDA-compliant manufacturing base, Nelabhotla stressed the urgent need to rapidly institutionalize advanced bioprocessing, complex biologics, and novel drug delivery systems (NDDS). This ensures Indian-made therapeutics meet the uncompromised quality standards of premium global markets.

4. COMMERCIALIZE: Global Reach and Elite Capital Markets

The final step focuses on orchestrating sophisticated global out-licensing structures and directly accessing elite global capital markets. Nelabhotla underscored this strategy by pointing to Vyome’s own major milestone: transitioning into a debt-free, publicly traded life sciences entity listed on the Nasdaq (Ticker: HIND).

Macro Context & Industry Drivers

The roadmap comes at a critical structural juncture for the Indian healthcare ecosystem, which is characterized by massive developmental strides juxtaposed against persistent funding gaps:

• The $1.1 Billion Paradox: While major Indian pharma groups are locked in high-stakes legal and regulatory battles globally, nimble players are using cross-border infrastructure to side-step legacy friction.
• Capital Disparity: Public healthcare spending in India remains historically low at 1% to 2.5% of GDP, creating an environment where deep-tech and life science ventures must aggressively court global institutional investments to fund long-gestation pipelines.
• The Talent Pivot: With more than 70% of specialized clinical infrastructure concentrated in urban hubs, cross-border biotech models allow Indian researchers to create global impact without succumbing to local infrastructure deficits.

“For India to orchestrate its next quantum leap, the industry must shed its risk-averse posture, embrace bold cross-border capital models, and aggressively pursue the commercialization of homegrown breakthrough science on the global stage.”

Venkat Nelabhotla, Pharma Leaders Summit 2026

The presentation concluded with a resounding call for collaborative disruption. By shifting from high-volume manufacturing to high-value IP ownership, the Indian pharmaceutical industry can successfully move up the value chain to develop, own, and commercialize next-generation cures directly for the global population.

Reflecting on the impact of the presentations, Dr. Satya Brahma, Chairman and Editor-In-Chief of Network 7 Media Group, emphasized the broader mission of the annual gathering and why blueprints like Vyome’s are essential for the industry’s future:  “This is not just a ceremony — it is a platform for visionary leadership. A movement of change, amplifying voices that challenge norms, disrupt complacency, and drive innovation.”— Dr. Satya Brahma, Chairman, Network 7 Media Group  This 17th Annual Pharma Leaders Healthcare Leadership Summit Overview features an in-depth look at the structural challenges and the transformative vision presented by top leaders during the 2026 Mumbai event.